Example of EMBO Molecular Medicine format
Recent searches

Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format Example of EMBO Molecular Medicine format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

EMBO Molecular Medicine — Template for authors

Publisher: EMBO Press
Categories Rank Trend in last 3 yrs
Molecular Medicine #9 of 167 down down by 3 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 414 Published Papers | 6331 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 27/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 8.2
SJR: 1.864
SNIP: 1.641
open access Open Access
recommended Recommended

Hindawi

Quality:  
High
CiteRatio: 6.4
SJR: 0.822
SNIP: 2.064
open access Open Access
recommended Recommended

American Chemical Society

Quality:  
High
CiteRatio: 6.5
SJR: 0.976
SNIP: 1.593
open access Open Access

American Chemical Society

Quality:  
High
CiteRatio: 8.1
SJR: 1.13
SNIP: 1.113

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

8.821

17% from 2018

Impact factor for EMBO Molecular Medicine from 2016 - 2019
Year Value
2019 8.821
2018 10.624
2017 10.293
2016 9.249
graph view Graph view
table view Table view

15.3

11% from 2019

CiteRatio for EMBO Molecular Medicine from 2016 - 2020
Year Value
2020 15.3
2019 17.2
2018 16.0
2017 15.7
2016 16.4
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 17% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has decreased by 11% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

4.923

2% from 2019

SJR for EMBO Molecular Medicine from 2016 - 2020
Year Value
2020 4.923
2019 4.816
2018 5.033
2017 5.44
2016 5.138
graph view Graph view
table view Table view

2.118

3% from 2019

SNIP for EMBO Molecular Medicine from 2016 - 2020
Year Value
2020 2.118
2019 2.057
2018 1.988
2017 2.122
2016 1.899
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 2% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 3% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
EMBO Molecular Medicine

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

EMBO Press

EMBO Molecular Medicine

EMBO Molecular Medicine is an open access journal dedicated to science at the interface between clinical research and the life sciences.... Read More

Molecular biology

i
Last updated on
27 Jun 2020
i
ISSN
1757-4676
i
Impact Factor
Maximum - 9.5
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
APA
i
Citation Type
Numbered
[25]
i
Bibliography Example
Beenakker, C.W.J. (2006) Specular andreev reflection in graphene.Phys. Rev. Lett., 97 (6), 067 007. URL 10.1103/PhysRevLett.97.067007.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.15252/EMMM.201606210
The amyloid hypothesis of Alzheimer's disease at 25 years
Dennis J. Selkoe1, John Hardy2
01 Jun 2016 - Embo Molecular Medicine

Abstract:

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer9s disease (AD). Confirmation that p... Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early, often initiating factor in Alzheimer9s disease (AD). Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ. Duplication of the wild‐type APP gene in Down9s syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD. Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain. Soluble oligomers of Aβ42 isolated from AD patients9 brains can decrease synapse number, inhibit long‐term potentiation, and enhance long‐term synaptic depression in rodent hippocampus, and injecting them into healthy rats impairs memory. The human oligomers also induce hyperphosphorylation of tau at AD‐relevant epitopes and cause neuritic dystrophy in cultured neurons. Crossing human APP with human tau transgenic mice enhances tau‐positive neurotoxicity. In humans, new studies show that low cerebrospinal fluid (CSF) Aβ42 and amyloid‐PET positivity precede other AD manifestations by many years. Most importantly, recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects. Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target. read more read less

Topics:

P3 peptide (60%)60% related to the paper, Biochemistry of Alzheimer's disease (59%)59% related to the paper, Presenilin (56%)56% related to the paper, Amyloid precursor protein (56%)56% related to the paper, Alzheimer's disease (55%)55% related to the paper
View PDF
3,824 Citations
open accessOpen access Journal Article DOI: 10.1002/EMMM.201100209
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Marilena V. Iorio, Carlo M. Croce1
01 Mar 2012 - Embo Molecular Medicine

Abstract:

Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based o... Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools. read more read less

Topics:

Cancer (51%)51% related to the paper
View PDF
1,565 Citations
open accessOpen access Journal Article DOI: 10.1002/EMMM.201100159
Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
01 Sep 2011 - Embo Molecular Medicine

Abstract:

A fat-enriched diet modifies intestinal microbiota and initiates a low-grade inflammation, insulin resistance and type-2 diabetes. Here, we demonstrate that before the onset of diabetes, after only one week of a high-fat diet (HFD), live commensal intestinal bacteria are present in large numbers in the adipose tissue and the ... A fat-enriched diet modifies intestinal microbiota and initiates a low-grade inflammation, insulin resistance and type-2 diabetes. Here, we demonstrate that before the onset of diabetes, after only one week of a high-fat diet (HFD), live commensal intestinal bacteria are present in large numbers in the adipose tissue and the blood where they can induce inflammation. This translocation is prevented in mice lacking the microbial pattern recognition receptors Nod1 or CD14, but overtly increased in Myd88 knockout and ob/ob mouse. This 'metabolic bacteremia' is characterized by an increased co-localization with dendritic cells from the intestinal lamina propria and by an augmented intestinal mucosal adherence of non-pathogenic Escherichia coli. The bacterial translocation process from intestine towards tissue can be reversed by six weeks of treatment with the probiotic strain Bifidobacterium animalis subsp. lactis 420, which improves the animals' overall inflammatory and metabolic status. Altogether, these data demonstrate that the early onset of HFD-induced hyperglycemia is characterized by an increased bacterial translocation from intestine towards tissues, fuelling a continuous metabolic bacteremia, which could represent new therapeutic targets. read more read less

Topics:

Bifidobacterium animalis (53%)53% related to the paper, Inflammation (51%)51% related to the paper, Adipose tissue (50%)50% related to the paper, Probiotic (50%)50% related to the paper
676 Citations
open accessOpen access Journal Article DOI: 10.1002/EMMM.200900041
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
01 Sep 2009 - Embo Molecular Medicine

Abstract:

The tumour suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers. Recent evidence suggests that PTEN is important for the maintenance of genome stability. Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumour cells. The HR ... The tumour suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers. Recent evidence suggests that PTEN is important for the maintenance of genome stability. Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumour cells. The HR deficiency caused by PTEN deficiency, sensitizes tumour cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo. PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2. The data we present here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours. read more read less

Topics:

PARP inhibitor (71%)71% related to the paper, PTEN (65%)65% related to the paper, Tensin (59%)59% related to the paper, DNA repair (52%)52% related to the paper, Mutation (51%)51% related to the paper
View PDF
633 Citations
open accessOpen access Journal Article DOI: 10.1002/EMMM.201202382
Resolution of inflammation: an integrated view
Almudena Ortega-Gomez1, Mauro Perretti2, Oliver Soehnlein1
01 May 2013 - Embo Molecular Medicine

Abstract:

Resolution of inflammation is a coordinated and active process aimed at restoration of tissue integrity and function. This review integrates the key molecular and cellular mechanisms of resolution. We describe how abrogation of chemokine signalling blocks continued neutrophil tissue infiltration and how apoptotic neutrophils ... Resolution of inflammation is a coordinated and active process aimed at restoration of tissue integrity and function. This review integrates the key molecular and cellular mechanisms of resolution. We describe how abrogation of chemokine signalling blocks continued neutrophil tissue infiltration and how apoptotic neutrophils attract monocytes and macrophages to induce their clearance. Uptake of apoptotic neutrophils by macrophages reprograms macrophages towards a resolving phenotype, a key event to restore tissue homeostasis. Finally, we highlight the therapeutic potential that derives from understanding the mechanisms of resolution. read more read less

Topics:

Tissue homeostasis (58%)58% related to the paper
View PDF
590 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for EMBO Molecular Medicine.

It automatically formats your research paper to EMBO Press formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

EMBO Molecular Medicine format uses APA citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write EMBO Molecular Medicine in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the EMBO Molecular Medicine guidelines and auto format it.

2. Do you follow the EMBO Molecular Medicine guidelines?

Yes, the template is compliant with the EMBO Molecular Medicine guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in EMBO Molecular Medicine?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the EMBO Molecular Medicine citation style.

4. Can I use the EMBO Molecular Medicine templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for EMBO Molecular Medicine.

5. Can I use a manuscript in EMBO Molecular Medicine that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper EMBO Molecular Medicine that you can download at the end.

6. How long does it usually take you to format my papers in EMBO Molecular Medicine?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in EMBO Molecular Medicine.

7. Where can I find the template for the EMBO Molecular Medicine?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per EMBO Molecular Medicine's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the EMBO Molecular Medicine's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. EMBO Molecular Medicine an online tool or is there a desktop version?

SciSpace's EMBO Molecular Medicine is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like EMBO Molecular Medicine?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like EMBO Molecular Medicine?”

11. What is the output that I would get after using EMBO Molecular Medicine?

After writing your paper autoformatting in EMBO Molecular Medicine, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is EMBO Molecular Medicine's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for EMBO Molecular Medicine?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for EMBO Molecular Medicine. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In EMBO Molecular Medicine?

The 5 most common citation types in order of usage for EMBO Molecular Medicine are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the EMBO Molecular Medicine?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per EMBO Molecular Medicine's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download EMBO Molecular Medicine in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in EMBO Molecular Medicine Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to EMBO Molecular Medicine formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template